ArticleImmunoTargets and therapy2026
Newcastle Disease Virus - Induced Interferons Regulate PD-L1 and MICA Expression in Human Tumor and Normal Cells.
Article in ImmunoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To explore whether NDV and/or NDV-induced IFNs regulate programmed death-1 ligand (PD-L1) expression and modulate the balance between inhibitory and stimulatory immune signals. Materials and Methods: Human non-malignant (NB1RGB and HEK293) and tumor (A549 and U87MG) cell lines were used. Cells were either infected with Newcastle disease virus (NDV) LaSota strain or treated with interferons (IFNs). PD-L1 expression was analyzed by flow cytometry, Western blotting, and immunofluorescence. The relationship between PD-L1, as an immune inhibitor, and major histocompatibility complex class I polypeptide-related sequence A (MICA), as an immune activator, was evaluated using duplex chromogenic in situ hybridization. To investigate whether the NDV-induced shift in the PD-L1/MICA axis was sufficient to activate natural killer group 2 member D (NKG2D) receptor-possessing cells within peripheral blood mononuclear cells (PBMCs), IFN-γ production was measured in PBMCs following 24 hours of co-culture with tumor and normal cell lines previously infected with NDV or treated with IFN-λ. Results: NDV infection and IFN treatment resulted in a reduction of PD-L1 expressions in specific cell types. This decrease was accompanied by a concurrent increase in MICA expression, as demonstrated by in situ hybridization. The shift in balance between PD-L1 and MICA correlated with enhanced activation of NKG2D receptor-expressing immune cells, evidenced by increased IFN-γ secretion. Conclusion: These findings suggest that NDV may exert antitumor effects by modulating the balance between inhibitory checkpoint molecules and stimulatory ligands, specifically through downregulation of PD-L1 and upregulation of MICA. This mechanism highlights the potential of NDV to enhance cytotoxic immune responses and supports its further development as a novel strategy in cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.